Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

PHASE4TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 29, 2022

Primary Completion Date

February 16, 2023

Study Completion Date

February 16, 2023

Conditions
Diabetes Mellitus, Type 2Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
DRUG

Semaglutide Pill

All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.

DIETARY_SUPPLEMENT

Fresh organic vegetables

Prescriptions of organic vegetables

Trial Locations (1)

93105

Sansum Diabetes Research Institute, Santa Barbara

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Sansum Diabetes Research Institute

OTHER